Market Intelligence

Japan In 2025: Policy Give, Pricing Take Set To Continue

 
• By 

While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.

As The Dust Settles, What Can We Learn From The J&J Vs. Auris Case?

 
• By 

In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.

Inside Recursion’s Pipeline: Najat Khan On AI, Data Science And Biotech Innovation

 
• By 

In Vivo caught up with Najat Khan, chief R&D and commercial officer at Recursion since mid-2024, about her new roles, the special combination with Exscientia and the company's clinical pipeline.

How Novo’s Acquisition Of Catalent Cleared European Regulators

 

Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?


Beyond CPAP: Apnimed’s Potential To Transform Sleep Apnea Management

 
• By 

Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.

Mixed Bag For Biopharma Funding In 2025: Dispatches From J.P. Morgan, Biotech Showcase

 
• By 

The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.

Roche’s Cardiometabolic Head Has Lilly and Novo In His Crosshairs

 
• By 

Manu Chakravarthy, Roche’s head of the resurrected cardiometabolic division, lays out his four-pillared strategy to place the company in direct competition with Eli Lilly and Novo Nordisk.

BioBytes: AI-Related Deals In Q4 ‘24

 
• By 

The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.


Only Half Of 2024’s Biggest Launches Belong To Big Pharma

 

Just a handful of big pharma approvals of 2024 are tipped to be multi-billion dollar blockbusters. Even though it is still early days for these drugs, the pull of M&A is looking increasingly strong for big pharma as more smaller firms go it alone.

Global Regulator Action To Improve Diversity In Clinical Trials

 
• By 

As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment. 

2024 Drug Launches Reflect A Breakout Year For Liver Disease

 

The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).

Podcast: Pre-JPM Biotech Dealmaking Panel

 
• By 

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.


From IPOs To Industrial M&A: The Evolution of China’s Pharmaceutical Dealmaking

 
• By 

In 2023, China emerged as the second largest exporter in the global biopharmaceutical pipeline. While innovation, international expansion, and commercialization remain pivotal, the industry's growth has increasingly relied on industrial efforts due to less active capital markets.

La French Touch: How France Has Built a Reputation for Excellence In Medtech

 

France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.

China Dominates APAC’s Emergence As Global Trials Hub

 
• By 

Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a Citeline White Paper shows.

Atopic Dermatitis: A Crowded Field With Room To Grow

 

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.


Data: The Clinical Trials Space Rebounds

 
• By 

The complex landscape of clinical trials, fraught with pressures and risks, and exacerbated by the adoption of new technologies, regulatory burdens, and drug pricing negotiations, is rebounding with aplomb.

Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics

 
• By 

Circular RNA has several advantages, but the field is young. Scandinavian startup Circio Holdings believes its version of the technology will prove the most robust.

Navigating The Uncharted Waters Of EU HTA

 
• By 

The EU-level joint clinical assessments that will be introduced under the Health Technology Assessment Regulation from January 2025 represent a huge shift for drug companies launching products in the EU. Industry experts Alexander Natz and Matias Olsen offer key advice to help companies prepare for what is to come.

Failing Fast: New And Strategic Ways To Prune Your Portfolio

 
• By 

AI and machine learning can help companies push failures further up to avoid costly late-stage disappointments.